Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Clinical trial NCT04164901 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04164901
- Sponsor
- Institut de Recherches Internationales Servier
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-05
- Primary completion
- 2022-09-06
- Enrollment
- 331
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.